ConcertAI announces the acquisition of CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). In conjunction with the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will enhance and expand CancerLinQ’s use of real-world data, analytics, next-generation AI, and other technologies to improve cancer care and speed clinical research. CancerLinQ represents one of the largest oncology real-world data and quality of care technology services entity in the world, uniquely bringing together clinical data from most major electronic medical record (EMR) systems.
Read the full article: ConcertAI to Acquire CancerLinQ to Build the Leading Healthcare Learning and Research Network in Oncology //
Source: https://www.prnewswire.com/news-releases/concertai-to-acquire-cancerlinq-to-build-the-leading-healthcare-learning-and-research-network-in-oncology-302010376.html